Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for fluoxetine hydrochloride submitted by Upsher-Smith Laboratories, LLC.
-
FDA approval · 2023-08-18FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) from Viatris Specialty LLC. The approval updates the …
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for fluoxetine hydrochloride from Dr. Reddy's Laboratories Limited. This is an approved amendmen…
-
FDA approval · 2023-08-18FDA Approved: VIIBRYD — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for Viibryd (vilazodone hydrochloride).
-
FDA approval · 2023-08-18FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
The FDA approved a supplemental application for paroxetine submitted by Padagis US LLC. This action represents an additional regulatory appr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-08-18FDA Approved: TRINTELLIX — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for TRINTELLIX (vortioxetine) submitted by Takeda Pharmaceuticals America, Inc., to update or expand…
-
FDA approval · 2023-08-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Venlafaxine Hydrochloride from Dr. Reddy's Laboratories Limited for a generic venlafaxine hydroc…
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine hydrochloride from Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-08-18FDA Approved: CITALOPRAM HYDROBROMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for citalopram hydrobromide from Aurobindo Pharma Limited, representing a generic version approval.
-
FDA approval · 2023-08-18FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Venlafaxine from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under an ANDA.
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: Telephone-Based Intervention to Treat Depression and Anxiety in Hispanic Cancer Survivors [NA]
A completed clinical trial tested a telephone-based intervention to treat depression and anxiety in Hispanic cancer survivors; results poste…
-
CLINICAL_TRIALS research · 2023-08-16Clinical Trial Update: Dialogical and Narrative Processes in Couple Therapy for Depression [Phase 2, Phase 3]
A completed clinical trial investigating dialogical and narrative processes in couple therapy for depression across Phase 2 and Phase 3.
-
FDA approval · 2023-08-16FDA Approved: DOXEPIN — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for a generic doxepin product (DOXEPIN) from Zydus Lifesciences Limited.
-
FDA approval · 2023-08-16FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved the original application for a generic doxepin hydrochloride product from Amneal Pharmaceuticals NY LLC. The generic is ind…
-
CLINICAL_TRIALS trial_result · 2023-08-15Clinical Trial Update: Clinical Study of GH001 in Depression [Phase 1, Phase 2]
Phase 1/2 clinical study of GH001 for treatment-resistant depression and major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-15Clinical Trial Update: Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents [Phase 2]
Phase 2 clinical trial investigating N-Ac for non-suicidal self-injury in adolescents has completed with results posted.
-
FDA approval · 2023-08-15FDA Approved: NORTRIPTYLINE HYDROCHLORIDE — Original Application (Advagen Pharma Ltd)
The FDA approved a generic formulation of nortriptyline hydrochloride from Advagen Pharma Ltd under an Original Application.
-
FDA approval · 2023-08-10FDA Approved: FLUOXETINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine from Torrent Pharmaceuticals Limited, enabling the generic antidepressant to be manuf…
-
FDA approval · 2023-08-09FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc., indicating an update to the produ…
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) [Phase 2, Phase 3]
A completed phase 2/3 trial comparing electroconvulsive therapy (ECT) to ketamine for treatment-resistant depression, with results posted in…
-
FDA approval · 2023-08-08FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved Amneal Pharmaceuticals of New York LLC's supplemental application to market a generic form of bupropion hydrochloride, indi…
-
FDA approval · 2023-08-02FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental ANDA for a generic formulation of bupropion hydrochloride by Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Healthy Minds Program App Dosage [Phase 1]
Phase 1 clinical trial update for the Healthy Minds Program App dosage addressing depression and anxiety; results posted in 2023.
-
FDA approval · 2023-07-28FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Dr. Reddys Laboratories Inc.)
FDA approved a supplemental application for Dr. Reddy's Laboratories' generic Bupropion Hydrochloride SR, expanding its regulatory approval …
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder [Phase 4]
Phase 4 trial update evaluating add-on sarcosine for efficacy and safety in major depressive disorder has completed.